Stephen Vintz
Analyst · Melissa Franchi with Morgan Stanley. Please proceed with your question
Thanks, Amit. As Amit mentioned earlier, we are very pleased with the results for the quarter and are excited about our outlook for 2020, which calls for continued growth and significant operating margin leverage as we scale our business to address a major market opportunity and cyber exposure. I’ll begin by reminding you that, except for revenue, all financial results we will discuss today are non-GAAP financial measures, unless stated otherwise. As Andrea mentioned at the start of this call, GAAP to non-GAAP reconciliations may be found in our earnings release issued earlier today and posted on our website. Before I discuss our fourth quarter results, I would like to also remind you that our results of operations reflects one month of activity for the Indegy acquisition. Consequently, Indegy’s revenue and calculated current billings are immaterial given the formative stages of the go-to-market activity. That said, our non-GAAP OpEx in the quarter reflects approximately $1.5 million from the impact of Indegy, primarily related to R&D expense and to a lesser extent, sales and marketing for headcount related to SCs with specific OT experience. From a GAAP perspective, we did incur cost related to the transfer of acquired intellectual property, as well as professional fees and the amortization of acquired intangible assets, which are detailed in the press release we issued today as well. Now on to our results for the quarter which is highlighted by record revenue, CCB and new enterprise customers. Revenue for the quarter was $97 million, which represents 29% growth over the same quarter last year. Revenue in the quarter exceeded the midpoint of our guided range by $3 million aided by strong execution both domestically and abroad. The upside revenue is a result of solid sales and a healthy intra-quarter flow due to some larger deals closing earlier than anticipated in the quarter. It is also worth noting that the quality of revenue is very strong as 93% of revenue is recurring which is a benefit of our subscription model. Calculated current billings defined as the change in current deferred revenue plus total revenue recognized in the quarter grew 28% year-over-year to $125 million. Overall, we’re very pleased with the positive trend line of CCB growth throughout the year, as growth increased from 25% in Q1, to 27% in Q2, to 28% in both Q3 and Q4. One of the drivers of CCB growth is the strength we are seeing in the enterprise market and our ability to transact larger deals. We added 461 new enterprise platform customers this quarter, which is a record and the first time you got it more than 400 in a single quarter. We attribute momentum here to the investments we've made in sales to grow ourselves what’s globally and in R&D to deliver continued innovation and differentiation. Not only are we seeing an acceleration of customers, but are also having success closing larger deals, as evidenced by the 52 net new six-figure customers in Q4. This brings the total number of customers spending in excess of $100,000 annually to 461 [Later changed by the Company to 641] and a notable increase over the 453 at the end of 2018. I’ll now turn to expenses and profitability. Gross margins were 82%, down from 84% in Q3 and 85% in Q4 2018 and is tracking in line with expectations. Our gross margin for the quarter reflects $1.6 million of additional costs related to the launch of Lumin including predictive analytics and data science and the amortization of capitalized software cost. As a reminder, we expect our gross margin to be in the low 80s to the high 70% range long-term. Now let’s turn to operating expenses. Sales and marketing expense is $57.7 million, compared to $53.2 million last quarter and $44.5 million in the fourth quarter last year. This represents 59% of revenue for the quarter and 60% for the full year, which is down from 62% in 2018. It’s also worth noting that the fourth quarter, it seems to be our largest quarter in terms of sales and this quarter was no different. As a result, we incurred higher sales incentive compensation on sequentially higher sales. Overall, we are very pleased with the leverage we demonstrated to-date which we attribute to a healthy productivity levels and a maturing sales force and continued progress is expected in 2020. R&D expense rose $20.4 million, compared to $18.6 million last quarter and $19 million in the fourth quarter last year. As a percent of revenue, R&D was 21%, compared to 25% in the same period last year. The increase over Q3 is primarily related to not capitalizing internal development cost associated with Lumin as well as the incremental cost from Indegy. G&A expense was $12.6 million, compared to $13.3 million last quarter and $11.2 million in the fourth quarter last year. As a percent of revenue, G&A was 13% this quarter which is down from 14% last quarter and 15% in the same period last year. Non-GAAP loss from operations was $11.1 million, compared to a loss of $7.7 million last quarter and $10.8 million in Q4 last year. Non-GAAP operating margin was negative 11%, compared to negative 8% last quarter and negative 14% of the fourth quarter last year. Again to summarize, our Non-GAAP op loss in the fourth quarter include $1.5 million of additional OpEx related to Indegy and $1.6 million of incremental expense related to Lumin as we are no longer capitalizing internal development costs related to this product. Overall, we’re very pleased with the significant operating leverage we have achieved to-date as our Non-GAAP operating margin for the full year increased from a negative 18% last year to negative 12% this year. Now all of this has translated positively to EPS. Our pro forma non-GAAP net loss per share for the fourth quarter was $0.11 which is two pennies better than the low-end of our guided range as adjusted for the Indegy acquisition. Now on to the balance sheet. We finished the fourth quarter with $212 million in cash and cash equivalents and short-term investments. Our cash balance reflects the cash consideration paid for the acquisition of Indegy. As part of the purchase accounting, we recorded $15.5 million of intangible assets associated with acquired technology, which will be amortized over seven years and $54 million of goodwill. Turning to cash flow, there a few discrete items impacting free cash flow this quarter such as, non-recurring payments related to the Indegy acquisition, primarily from income taxes and other costs related to the IP transfer, as well as CapEx for our new headquarters and the benefits from the SPP activity that we highlighted in our press release and in our prior conference calls. That said, our free cash flow burn was $13.5 million for the quarter. However, excluding these items our cash flow would have been positive for the quarter. With the results of the quarter behind us, I’d like to now discuss our 2020 outlook. I’ll start by echoing Amit’s comments on balanced growth. With over 90% recurring revenue, 80% gross margins, increasing enterprise penetration and strong unit economics, we have confidence in our ability to sustain attractive long-term growth and are committed to becoming a role of 40 company. Accordingly, our 2020 guidance reflects progress towards achieving this. Recall, we previously stated that we intend to turn free cash flow positive by the time we exit 2020. Today, I am pleased to add that we expect to generate positive free cash flow for the full year and expect our free cash flow margins to increase over time. In terms of expense flow in 2020, we expect total operating expenses to increase sequentially in Q1 due to the timing of industry and other events, as well as the inclusion of Indegy for a full quarter. For the remainder of the year, we expect operating expenses to grow more modestly than the years past, which is contemplated in our annual guidance and reflects improved operating margins. Essentially, the Indegy acquisition allowed us to accelerate investments that we otherwise would have made throughout the year. With that as a backdrop let’s turn to guidance. For the first quarter of 2020, we currently expect, revenue to be in the range of $100 million to 101 million. Non-GAAP loss from operations to be the range of $18 million to $17 million. Non-GAAP net loss in the range of $19 million to $18 million and pro forma non-GAAP net loss per share in the range of $0.19 to $0.18 assuming weighted average common shares outstanding of 98.7 million. For the full year 2020, we currently expect revenue of $435 million to $440 million, Calculated current billings of $500 million to $510 million. Non-GAAP loss from operations in the range of $38 million to $33 million. Non-GAAP net loss in the range of $41 million to $36 million. Pro forma non-GAAP net loss per share in the range of $0.41 to $0.36 assuming weighted average common shares outstanding of $100.1 million. For the full year our CCB guidance reflects strength in our core business with modest contributions from our newly launched Lumin product and OT offering. We are seeing good early momentum from our more expansive product portfolio. But we expect the contribution from newer products to build over time. The non-GAAP net loss for the full year assumes a provision for income taxes of approximately $6.5 million. This amount is highly dependent on the allocation of income by jurisdictions, as well as non-resident withholding taxes. In summary, we are pleased with our Q4 and 2019 full year results and believe we are positioned well for continued success. And now I will turn the call back to Amit for some closing comments.